{"id":"cd0271-0-1-cd1579-2-5","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination topical product in development by Galderma for dermatological use. CD0271 and CD1579 are combined at specific concentrations (0.1% and 2.5% respectively) to provide enhanced therapeutic efficacy. The exact molecular targets and mechanisms require proprietary information from Galderma's development program.","oneSentence":"CD0271 and CD1579 are topical agents that work synergistically to reduce skin inflammation and improve dermatological conditions through complementary anti-inflammatory pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:10.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dermatological inflammatory condition (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT01688531","phase":"PHASE1","title":"A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-08","conditions":"Acne","enrollment":38},{"nctId":"NCT01880320","phase":"PHASE3","title":"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Acne Vulgaris","enrollment":503},{"nctId":"NCT02073448","phase":"PHASE3","title":"Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-03","conditions":"Acne Vulgaris","enrollment":417}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CD0271 0.1% / CD1579 2.5%","genericName":"CD0271 0.1% / CD1579 2.5%","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CD0271 and CD1579 are topical agents that work synergistically to reduce skin inflammation and improve dermatological conditions through complementary anti-inflammatory pathways. Used for Dermatological inflammatory condition (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}